A 64-year-old man was referred to our hospital for workup of a pancreatic mass. Ultrasonography revealed dilatation of the main pancreatic duct (MPD) in the body and tail of the pancreas [ Figure 1a ]. Abdominal computed tomography demonstrated a mass in the head of the pancreas with gradual enhancement [ Figure 1b ]. EUS showed a hypoechoic mass in MPD, measuring about 16 mm × 14 mm, with dilatation of MPD in the pancreatic body and tail [ Figure 1c ]. Endoscopic retrograde pancreatography showed obstruction of MPD in the head of the pancreas [ Figure 1d ], and we performed biopsy of the lesion. Histological examination of the biopsy specimen suggested combined carcinoma with both ductal and neuroendocrine features.
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Subtotal stomach-preserving pancreatoduodenectomy was performed. Macroscopically, MPD was occluded by a solid tumor, which measured 16 mm × 8 mm in size and extended 33 mm in length, while we could not find a macroscopic solid lesion in the parenchyma. Microscopically, the tumor consisted of two components: one was a ductal component of cells with irregularly shaped nuclei and conspicuous nucleoli [ Figure 2a and b] and the other was a neuroendocrine component of cells with round nuclei, "salt-and-pepper" chromatin, and eosinophilic
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This is an open access journal, and articles are distributed underthe terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, andbuild upon the work non-commercially, as long as appropriate creditis given and the new creations are licensed under the identical terms. Images and Videos cytoplasm [ Figure 2c ]. The transitional zone with minimal invasion into the pancreatic parenchyma was observed in the branch duct adjacent to MPD [ Figure 2d ]. Immunohistochemically, the former component was positive for cytokeratin-19, CA19-9, and carcinoembryonic antigen (CEA) [Figure 2e ], but not for endocrine markers [Figure 2f ], while the latter was positive for chromogranin A and synaptophysin [ Figure 2g ], not for CEA [ Figure 2h ]. Ki-67 labeling index was over 20% in an endocrine element. Each component comprised more than one-third of the neoplastic tissue; therefore, we finally diagnosed it as mixed ductal-neuroendocrine carcinoma.
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Pancreatic mixed ductal-neuroendocrine carcinoma is a rare tumor whose frequency in pancreatic tumors is <0.2% [1] and reveals expanding or invasive growth in the pancreatic parenchyma. [2] There has been only one case report of minute mixed ductal-neuroendocrine carcinoma with predominant intraductal growth similar to this case. [3] In this case, we assume that ductal adenocarcinoma would be initially derived from an intraepithelial lesion in the branch duct adjacent to MPD and that it would partially differentiate into neuroendocrine carcinoma during the growth in MPD. This resulted in a very rare case of unique mixed ductal-neuroendocrine carcinoma with predominant intraductal growth in MPD without a macroscopic intraparenchymal lesion.
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